Investment Summary

Allergy Therapeutics PLC is a specialty pharmaceutical company focused on the diagnosis, prevention and treatment of allergic disease through subcutaneous immunotherapy. The company has built a differentiated Franchise in selected European markets, particularly Germany, the United Kingdom, Italy, Austria, Switzerland, Spain and the Netherlands, and is developing a pipeline of next-generation allergy immunotherapy products with applications across both adult and paediatric populations. With rising global prevalence of allergic disease, continued Demand for disease-modifying immunotherapy and a maturing pipeline including ultra-short-course products and adjuvanted formulations, the company offers meaningful long-term opportunity. We rate the shares a Buy.

Business Overview

Allergy Therapeutics is headquartered in Worthing, United Kingdom, with Manufacturing capabilities in Worthing and a commercial footprint across continental Europe. The company is listed on the AIM market of the London Stock Exchange. Its product portfolio focuses on subcutaneous immunotherapy, with branded products treating allergies to grass pollen, tree pollen, weed pollen, house dust mite, animal dander and Hymenoptera (bee and wasp) venom. The Pollinex Quattro range, the company's flagship franchise, is a short-course subcutaneous immunotherapy regimen administered before the allergy season, typically requiring four injections rather than the multi-year courses required by traditional immunotherapy approaches.

Beyond commercial products, the company is developing an active pipeline that includes registration-stage products targeting tree and grass pollen allergens in the United States and Europe, and earlier-stage programmes in food allergy, peanut allergy and other indications. The combination of commercial Revenue, a substantive pipeline and continued investment in manufacturing capability provides a balanced specialty pharmaceutical profile.

Sector Backdrop

Allergic disease is one of the most prevalent chronic conditions globally, with estimates suggesting that 20 to 30 percent of the population in developed countries experiences some form of allergic disease, including allergic rhinitis, asthma, food allergy, eczema and venom allergy. Prevalence continues to rise, attributed to a combination of environmental, dietary, behavioural and immunological factors. Standard symptomatic treatments, including antihistamines, decongestants and topical corticosteroids, address symptoms but do not modify the underlying immune dysfunction. Allergen-specific immunotherapy, delivered subcutaneously or sublingually, is the only treatment that targets the underlying immune mechanism and can deliver long-lasting disease modification. Despite this, market penetration of immunotherapy remains relatively low, suggesting substantial growth potential. Patient and physician interest in disease-modifying therapies, advances in formulation science and growing recognition of the systemic burden of allergic disease all support a positive long-term sector outlook.

Investment Thesis

Our positive view rests on several pillars. First, the company has built an established commercial franchise across European markets where allergy immunotherapy is well-recognised by allergists, paediatricians and family physicians. Second, the Pollinex Quattro short-course regimen offers a meaningful patient experience advantage over conventional long-course immunotherapy, supporting strong Brand loyalty. Third, the pipeline includes registration-stage products with significant commercial potential, particularly in the United States, where the allergy immunotherapy market is large but largely served by sublingual tablets rather than the differentiated subcutaneous approach offered by the company. Fourth, the company's manufacturing capability, regulatory expertise and clinical experience provide barriers to entry that protect existing commercial revenue. Fifth, recent strategic and financial restructuring has stabilised the Balance Sheet and supports continued investment in pipeline and commercialisation. Sixth, the valuation reflects significant pessimism about the path forward, providing Leverage to positive pipeline news flow and operational improvement.

Growth Drivers

Several specific drivers reinforce the medium-term outlook. The continued penetration of Pollinex Quattro across core European markets supports stable to growing commercial revenue. New formulation and presentation improvements expand patient and prescriber acceptance. Geographic expansion into additional European countries, supported by regulatory approvals and partner-led commercialisation, provides incremental revenue. The pipeline of registration-stage products, including grass pollen and tree pollen immunotherapy for the US market, represents a major potential value catalyst, with the US allergy market significantly larger than the European franchise. Earlier-stage programmes, including food allergy approaches and adjuvanted formulations using next-generation technologies, provide longer-term optionality. Continued investment in manufacturing capability, including capacity expansion and process improvement, supports both existing revenue and pipeline launches.

Financial Performance

Allergy Therapeutics has historically delivered solid revenue growth from its commercial product franchise, partially offset by significant pipeline investment that has driven operating losses in recent years. Recent restructuring efforts have included strategic financing, operational efficiency programmes and prioritisation of highest-conviction pipeline Assets, improving the financial profile. Cash Management remains a key focus given the company's stage of development. The completion of pivotal Clinical Trials and the progression towards regulatory filings represent important milestones that may unlock additional Capital, Partnership opportunities or commercial revenue. As pipeline assets progress and commercial revenue continues to grow, the financial profile is expected to improve materially.

The German market deserves particular focus given its size and importance to the company's commercial franchise. Germany is one of the largest allergy immunotherapy markets in Europe, with strong clinical recognition of disease-modifying treatment, well-established reimbursement pathways and a deep ecosystem of allergists, dermatologists and general practitioners. Allergy Therapeutics has built a strong commercial presence in Germany over many years, with Brand Recognition, sales force capability and clinical evidence supporting prescriber preference. Continued investment in clinical evidence, real-world data and brand support is expected to maintain market leadership in this critical geography.

Differentiated Technology Platform

Allergy Therapeutics has developed a differentiated technology platform that combines allergen extracts with proprietary adjuvants designed to enhance immune response while reducing the number of injections required. MicroCrystalline Tyrosine, the company's adjuvant platform, has been used in its commercial subcutaneous immunotherapy products for decades and provides a depot effect that supports the short-course regimen. The combination of allergen extracts with the TLR4 agonist monophosphoryl lipid A in Pollinex Quattro has been shown in clinical trials to deliver strong clinical efficacy with a favourable safety profile. This technology platform also provides applications in additional indications, including food allergy, and may have potential adjuvant applications beyond classical allergy immunotherapy. The breadth and depth of the platform represents a meaningful asset that supports both existing products and pipeline development.

Pipeline and Clinical Outlook

The pipeline is anchored by registration-stage programmes in tree pollen and grass pollen immunotherapy. Pivotal trials, regulatory engagement and dossier preparation are at various stages of progression. Successful regulatory approval and commercial launch in the United States could materially expand the addressable market and represent a transformational event for the company. Beyond these flagship programmes, earlier-stage development includes peanut allergy immunotherapy, where unmet need is high and existing commercial Options have limitations, and other food allergy programmes. Adjuvant technology investments, including the MicroCrystalline Tyrosine adjuvant and TLR4 agonists, provide a unique technology platform with potential applications beyond classical allergy. The combination of late-stage and earlier-stage assets provides multi-year news flow and value creation potential.

Commercialisation Outlook

Commercialisation in core European markets is supported by an experienced field force, longstanding relationships with allergists and paediatricians, and educational and patient support initiatives. The differentiated short-course regimen provides a clear value proposition relative to conventional immunotherapy. For potential US launches, the company is evaluating commercial strategies including partnerships with established allergy distributors, direct commercialisation through a focused field force, or hybrid approaches. The US allergy immunotherapy market is sizeable and has been growing, though the commercial landscape includes both sublingual tablets and traditional subcutaneous extracts, requiring careful positioning. Investment in clinical education, real-world evidence and patient support will be important to successful commercial launches.

Capital Structure and Strategic Outlook

Allergy Therapeutics has been working through a period of strategic and financial restructuring designed to stabilise the balance sheet, refocus the pipeline and align the cost base with priorities. The combination of operational improvement, pipeline progression and selective partnership opportunities provides flexibility to fund ongoing development. Capital allocation priorities are pipeline advancement, manufacturing investment and commercial expansion, with Shareholder returns expected to follow once profitability is sustained. Strategic options including partnerships, licensing arrangements and selective M&A may also be considered as appropriate.

Valuation Perspective

Allergy Therapeutics trades on a depressed valuation that reflects historical execution challenges, recent restructuring activities and uncertainty about the path forward. We believe this valuation does not adequately reflect the long-term opportunity represented by the existing commercial franchise, the late-stage pipeline and the technology platform. Successful regulatory approvals, particularly for US launches, would represent a meaningful re-rating catalyst. Even applying conservative probability-weighted assumptions, scenario analysis points to material upside from current levels. The shares are best suited to long-term investors prepared to accept the Volatility inherent in specialty pharmaceutical development.

Key Risks

Risks include clinical trial outcomes, regulatory approvals (particularly for US registration), commercial execution in new geographies, manufacturing complexity inherent in biological immunotherapy products, competition from sublingual tablets and existing subcutaneous extracts, cash management and potential for additional capital requirements, and macroeconomic exposure. Reimbursement frameworks for allergy immunotherapy vary across countries and may evolve in ways that affect commercial Economics. Patent and intellectual property protection across formulations and adjuvant technologies is critical.

Sustainability and Stakeholder Strategy

Allergy Therapeutics emphasises its mission of addressing the underlying immune drivers of allergic disease, supporting better long-term outcomes for patients. Sustainability efforts include environmental management at manufacturing sites, ethical clinical trial conduct, patient advocacy support and engagement with allergy patient communities. Strong governance, board oversight and transparent reporting support stakeholder confidence as the company progresses through its strategic plan.

Specialist Market Demand and Patient Population

The patient population for allergy immunotherapy continues to expand globally. Allergic rhinitis affects an estimated 10 to 30 percent of adults and up to 40 percent of children across major developed economies. Allergic asthma frequently co-exists with allergic rhinitis and represents a more severe manifestation of the underlying immune dysfunction. Food allergy prevalence has been rising particularly rapidly, particularly peanut and tree nut allergies, which can have severe and even life-threatening consequences. Despite this large patient pool, immunotherapy remains underused, with most patients managed only with symptomatic medications that do not address underlying immune drivers. Increased public awareness of allergy immunotherapy as a disease-modifying option, supported by clinical evidence demonstrating long-term efficacy and economic benefit, represents a structural opportunity for established providers like Allergy Therapeutics.

Specialist physician engagement is a critical asset. Allergists, ENT specialists, paediatricians and dermatologists are central to immunotherapy prescribing decisions and play a key role in patient education, treatment selection and ongoing care. Allergy Therapeutics has built deep relationships with these specialist communities across its core markets, supported by clinical evidence, medical education programmes, expert advisory boards and patient support services. The company's involvement in clinical research, real-world evidence generation and continuing medical education further reinforces its credibility with the specialist community.

Conclusion: Why We Rate Allergy Therapeutics a Buy

Allergy Therapeutics PLC offers leveraged exposure to the structural growth of allergy immunotherapy through both an established European commercial franchise and a maturing development pipeline with significant US potential. With operational restructuring delivering improvements, pipeline assets progressing towards key regulatory milestones and a depressed valuation reflecting historical concerns, the risk-reward is asymmetrically attractive for long-term investors. We therefore rate Allergy Therapeutics PLC a Buy. Patient investors prepared to navigate the higher volatility characteristic of specialty pharmaceutical names should find the long-term opportunity in allergy immunotherapy a compelling addition to a diversified healthcare portfolio.